Julian Upton

LEO Pharma CEO Gitte Aabo talks to PE about issues pertinent to the dermatology therapy area and how LEO's unconventional business model is helping the company achieve its objectives.

Pharma is no stranger to multi-channel marketing, but, according to Novartis's Panos Papakonstantinou, the industry still isn't getting it right.Pharma is no stranger to multi-channel marketing (MCM), but, according to Panos Papakonstantinou, Novartis's Head, Digital Commercial, Europe, the industry still needs to perfect its approach to MCM. Pharm Exec met up with Panos at last week's eyeforpharma Barcelona event to find out what needs to be done. 

Pharm Exec talks value-based healthcare with Professor Bengt Jönsson of the Stockholm School of Economics.

Anti-corruption NGO Transparency International now has pharma in its sights. Pharm Exec speaks to Sophie Peresson, Director of its Pharmaceuticals & Healthcare Program.

February 09, 2016.

Pharm Exec talks to Jane Griffiths, Company Group Chairman, Janssen EMEA, about how the relationship between industry and patients is maturing.

Pharm Exec interviews Subhanu Saxena, CEO of India pharma giant Cipla, who discusses the longtime emerging market champion’s strategic plans to raise its geographic profile and secure the company’s future in the US.

It’s easy to foresee controversy in 2016 as lagging global economic growth and a messy US political slugfest force the pharma industry’s feet to the fire. Can the industry reclaim a semblance of public approval by confronting its pricing demons and focusing on innovation and a fresh, patient-first message?

Julian Upton sits down with Subhanu Saxena for an update on Cipla's plans to leverage its historic visibility as an emerging market champion to the next level of global leadership in biopharma.

In Pharm Exec’s 2013 end-of-year supply chain roundup, we began with a three-word vision of the immediate future that left little room for ambiguity: “Serialization is coming.” With the impending laws regarding “track and trace” promising to alter the way pharmaceuticals are packaged and shipped, we outlined how global pharma was gearing up to deal with the effects of serialization, and how companies needed to review their own internal practices and those of their outsourcing partners, as the need for technology solutions for both sides of the outsourc

Pharm Exec speaks to Physicians Interactive CEO Donald Tramuto to understand about the key trends shaping the future of e-health.

A recent survey of European biopharma companies and board members revealed that 80 percent of firms find access to qualified senior executives to be a challenge, with the toughest spot to fill being the "seasoned CEO".

With the talk shifting (again) to a Greek exit from the Eurozone, what is pharma thinking?

May 11, 2015.

Inspired by TV’s Mad Men, Julian Upton puts himself into a 1960 executive’s shoes to describe the “ethical pharma” industry of half a century ago

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London.

The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.

Research advocate, "cancer warrior" and survivor Jack Whelan talks to Pharm Exec about what pharma how pharma could improve its communication with patients.

Pharma and healthcare are among the many areas being viewed with increasing attention inside and outside Greece, following the victory in the country’s elections of the radical left-wing, anti-austerity Syriza party.

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

When he left school, Ian Harris wanted a career in brewing. He enrolled on a biochemistry degree with the intention of going on to study a master’s in brewing at Heriot-Watt University in Edinburgh, UK

The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices.

The UK government pledged late last year that it would double funding for dementia research by 2025 (from £66m [US$112m] in 2015 to £122m [US$207m]), but today Prime Minister David Cameron spoke on the subject again in light of expert warnings that little progress is being made.

They say the road to hell is paved with good intentions.

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions.

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.

Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years.

For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive - muddling through is so yesterday.

European Union (EU) regulators today reached agreement on the much-vaunted Clinical Trials Regulation. The regulation harmonizes the rules for the conduct of clinical trials in the EU and the ‘acceptability’ of the resulting data, and places further safeguards on the safety of trial subjects.

The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).